Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strattera Cleared For Longer Use In ADHD Kids

This article was originally published in The Pink Sheet Daily

Executive Summary

Trial data could reassure doctors about treating as needed, Lilly says.

You may also be interested in...



FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD

British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.

Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%

Shire plans to launch its nonstimulant ADHD candidate Intuniv in the second half of 2009, though new studies may be required to gain FDA approval

Strattera Suicidal Thinking Data Is Of Little Clinical Significance, Lilly Consultants Say

Data analysis used as the basis for a public health advisory on Lilly’s Strattera in children and adolescents is unreliable, SUNY Upstate Medical University, Columbia University professors say.

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel